In adoptive cellular therapy, T cells are removed from a patient, genetically modified or treated with chemicals to enhance their activity, and then re-introduced into the patient with the goal of improving the immune system's anti-cancer response.
A T cell or T lymphocyte is a type of lymphocyte (a subtype of white blood cell) that plays a central role in cell-mediated immunity.
Natural Killer Cells can work in cancer treatment by being modified to recognize and attack tumor cells in the body. Natural Killer Cells are already found in the body, and are unique because they are able to recognize and attack cells without being acted upon by an antigen (immunization).
JNJ-68284528 (LCAR-B38M) is an autologous CAR-T therapy that targets B-Cell Maturation Antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. The investigational therapy expresses an identical CAR protein as Legend's LCAR-B38M CAR-T product, which was evaluated in a first-in-human clinical study (Legend-2) conducted in multiple sites by Legend Biotech in China.
bb2121 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily. When it finds myeloma cells, bb2121 removes and destroys them.
CAR2 Anti-CD38 A2 CAR-T Cells has the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity. CAR2 Anti-CD38 A2 CAR-T Cells are being evaluated in multiple myeloma (MM) and has successfully demonstrated strong preclinical anti-tumor activity in animal models.
bb21217 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily.
Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.
JCARH125 is a CAR T-cell product that targets B-cell maturation antigen (BCMA).
Create your account today and get matched to myeloma treatments and trials around the US.
Weekdays 9am - 5pm EST